Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - trametiniib - melanoom - antineoplastilised ained - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. mitteväikerakk-kopsuvähk (mitteväikerakk-kopsuvähi)trametinib koos dabrafenib on näidustatud ravi täiskasvanud patsientidel, kaugelearenenud mitteväikerakk-kopsuvähi, mille braf v600 mutatsioon.

Eesti - eesti - Ravimiamet

novartis pharma services ag - trametiniib - suukaudse lahuse pulber - 5mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanoom - antineoplastilised ained - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. abiaine ravi melanomadabrafenib koos trametinib on näidustatud abiaine ravi täiskasvanud patsientidel, kellel on iii etapp melanoom, mille braf v600 mutatsioon, pärast täielik resektsioon. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.